BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9112687)

  • 21. Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.
    Matsuda A; Kosaki H; Saitoh Y; Yoshimura Y; Minakawa N; Nakata H
    J Med Chem; 1998 Jul; 41(15):2676-8. PubMed ID: 9667957
    [No Abstract]   [Full Text] [Related]  

  • 22. A Purinergic Trail for Metastases.
    Ferrari D; Malavasi F; Antonioli L
    Trends Pharmacol Sci; 2017 Mar; 38(3):277-290. PubMed ID: 27989503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory purinergic P2 receptor characterisation in rat distal colon.
    Van Crombruggen K; Van Nassauw L; Timmermans JP; Lefebvre RA
    Neuropharmacology; 2007 Aug; 53(2):257-71. PubMed ID: 17612577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New targets for drug therapeutics: receptors for purines and pyrimidines].
    Ren LM; Zhang M; Yao SK; Zhu ZN
    Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):116-20. PubMed ID: 12889142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits.
    Khakh BS; Burnstock G; Kennedy C; King BF; North RA; Séguéla P; Voigt M; Humphrey PP
    Pharmacol Rev; 2001 Mar; 53(1):107-18. PubMed ID: 11171941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters.
    Volonté C; D'Ambrosi N
    FEBS J; 2009 Jan; 276(2):318-29. PubMed ID: 19076212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P2Y receptors: biological advances and therapeutic opportunities.
    Shaver SR
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):665-70. PubMed ID: 12825461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P2 receptors and cancer.
    White N; Burnstock G
    Trends Pharmacol Sci; 2006 Apr; 27(4):211-7. PubMed ID: 16530853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P2X and P2Y receptors as possible targets of therapeutic manipulations in CNS illnesses.
    Köles L; Furst S; Illes P
    Drug News Perspect; 2005 Mar; 18(2):85-101. PubMed ID: 15883618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The pharmacology of purine receptors].
    Sergeev PV; Shimanovskiĭ NL
    Farmakol Toksikol; 1987; 50(1):115-23. PubMed ID: 3549353
    [No Abstract]   [Full Text] [Related]  

  • 31. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
    Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
    BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adenosine receptors. Principle for the development of new drugs].
    Fischer I
    Med Monatsschr Pharm; 1990 Jul; 13(7):202-3. PubMed ID: 2377132
    [No Abstract]   [Full Text] [Related]  

  • 33. Purinergic actions on neurons that modulate nociception in the rostral ventromedial medulla.
    Selden NR; Carlson JD; Cetas J; Close LN; Heinricher MM
    Neuroscience; 2007 Jun; 146(4):1808-16. PubMed ID: 17481825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purinoceptors modulating the release of noradrenaline.
    von Kügelgen I
    J Auton Pharmacol; 1994 Feb; 14(1):11-2. PubMed ID: 8150807
    [No Abstract]   [Full Text] [Related]  

  • 35. ATP and adenosine inhibit transmitter release at the frog neuromuscular junction through distinct presynaptic receptors.
    Giniatullin RA; Sokolova EM
    Br J Pharmacol; 1998 Jun; 124(4):839-44. PubMed ID: 9690879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proposal of a guanine-based purinergic system in the mammalian central nervous system.
    Schmidt AP; Lara DR; Souza DO
    Pharmacol Ther; 2007 Dec; 116(3):401-16. PubMed ID: 17884172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications.
    Antonioli L; Colucci R; Pellegrini C; Giustarini G; Tuccori M; Blandizzi C; Fornai M
    Pharmacol Ther; 2013 Aug; 139(2):157-88. PubMed ID: 23588157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells.
    Kim MS; Lee J; Ha J; Kim SS; Kong Y; Cho YH; Baik HH; Kang I
    Arch Biochem Biophys; 2002 May; 401(2):205-14. PubMed ID: 12054471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Heterodimerization of G protein-coupled receptors].
    Nakata H
    Nihon Yakurigaku Zasshi; 2007 Jul; 130(1):4-8. PubMed ID: 17634672
    [No Abstract]   [Full Text] [Related]  

  • 40. Adenosine receptors.
    Palmer TM; Stiles GL
    Neuropharmacology; 1995 Jul; 34(7):683-94. PubMed ID: 8532135
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.